A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02963077 |
Recruitment Status :
Completed
First Posted : November 15, 2016
Last Update Posted : November 16, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Orphan Cholestatic Liver Diseases Primary Biliary Cirrhosis Progressive Familial Intrahepatic Cholestasis Alagille Syndrome | Drug: A4250 Drug: CRC (A3384) Drug: Questran Drug: Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 94 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy Subjects |
Study Start Date : | July 2013 |
Actual Primary Completion Date : | May 2014 |
Actual Study Completion Date : | May 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1 SAD - 0.1 mg A4250
Dose: 0.1 mg of A4250. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
|
Drug: A4250 |
Experimental: Cohort 2 SAD - 0.3 mg A4250
Dose: 0.3 mg of A4250.
|
Drug: A4250 |
Experimental: Cohort 3 SAD - 1 mg A4250
Dose: 1 mg A4250.
|
Drug: A4250 |
Experimental: Cohort 4 SAD - 3 mg A4250
Dose: 3 mg A4250.
|
Drug: A4250 |
Experimental: Cohort 5 SAD - 10 mg A4250
Dose: 10 mg A4250.
|
Drug: A4250 |
Placebo Comparator: Cohort 1 SAD placebo
Dose: 0.1 mg of A4250 matching placebo. Sentinel dosing was used (2 sub-cohorts dosed a minimum of 24 h apart).
|
Drug: Placebo |
Placebo Comparator: Cohort 2 SAD placebo
Dose: 0.3 mg A4250 matching placebo.
|
Drug: Placebo |
Placebo Comparator: Cohort 3 SAD placebo
Dose: 1 mg A4250 matching placebo.
|
Drug: Placebo |
Placebo Comparator: Cohort 4 SAD placebo
Dose: 3 mg A4250 matching placebo.
|
Drug: Placebo |
Placebo Comparator: Cohort 5 SAD placebo
Dose: 10 mg A4250 matching placebo.
|
Drug: Placebo |
Experimental: Cohort 1 MAD - 1 mg A4250 qd
Dose: 1 mg A4250 qd for 7 days.
|
Drug: A4250 |
Placebo Comparator: Cohort 1 MAD placebo
Dose: 1 mg A4250 matching placebo qd for 7 days.
|
Drug: Placebo |
Experimental: Cohort 2 MAD - 3 mg A4250
Dose: 3 mg A4250 qd for 7 days
|
Drug: A4250 |
Placebo Comparator: Cohort 2 MAD placebo
Dose: 3 mg A4250 matching placebo qd for 7 days.
|
Drug: Placebo |
Experimental: Cohort 3 MAD - 1.5 mg A4250 b.i.d for 7 days.
Dose: 1.5 mg A4250 b.i.d. for 7 days.
|
Drug: A4250 |
Placebo Comparator: Cohort 3 MAD placebo
Dose: 1.5 A4250 matching placebo b.i.d for 7 days.
|
Drug: Placebo |
Experimental: Cohort 4 MAD - 3 mg A4250 qd + 1 mg Questran b.i.d
Dose: 3 mg A4250 qd + 1 mg Questran b.i.d for 7 days.
|
Drug: A4250 Drug: Questran |
Active Comparator: Cohort 4 MAD A4250 placebo + 1 mg Questran b.i.d
Dose: 3 mg A4250 matching placebo + 1 mg Questran b.i.d for 7 days.
|
Drug: Questran Drug: Placebo |
Experimental: Cohort 5 MAD - 3 mg A4250 qd + 1 g CRC b.i.d
Dose: 3 mg A4250 qd + 1 g CRC b.i.d for 7 days.
|
Drug: A4250 Drug: CRC (A3384) |
Placebo Comparator: Cohort 5 MAD A4250 placebo + CRC placebo
Dose: 3 mg A4250 matching placebo qd + 1 g CRC placebo b.i.d for 7 days
|
Drug: Placebo |
Active Comparator: Cohort 6 MAD - 1 g CRC
Dose: 1 g CRC b.i.d
|
Drug: CRC (A3384) |
Placebo Comparator: Cohort 6 MAD CRC placebo
Dose: 1 g CRC matching placebo b.i.d.
|
Drug: Placebo |
Experimental: Cohort 7 MAD - 3 mg A4250 qd + 1 g CRC b.i.d
Dose: 3 mg A4250 qd + 1 g CRC b.i.d
|
Drug: A4250 Drug: CRC (A3384) |
Placebo Comparator: Cohort 7 MAD A4250 placebo + CRC placebo
Dose: 3 mg A4250 matching placebo qd + 1 g CRC matching placebo b.i.d.
|
Drug: Placebo |
- Mean (± SD) Plasma Pharmacokinetic Concentrations of A4250 Following A Single Oral 10 mg A4250 Dose - Tmax [ Time Frame: Pharmacokinetic blood samples were taken pre-dose, and post-dose at: 0.5 hour, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours ]
- Mean (± SD) Plasma Pharmacokinetic Concentrations of A4250 Following a Single Oral 10 mg A4250 Dose - Cmax [ Time Frame: Pharmacokinetic blood samples were taken pre-dose, and post-dose at: 0.5 hour, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours ]
- Mean (± SD) Plasma Pharmacokinetic Concentrations of A4250 Following a Single Oral 10 mg A4250 Dose - AUC 0-t [ Time Frame: Pharmacokinetic blood samples were taken pre-dose, and post-dose at: 0.5 hour, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours ]
- Mean (SD) Change in FGF19 from Day 1 Pre-Dose to 4 h Post-Dose [ Time Frame: Pharmacodynamic blood samples were taken pre-dose and at 4 hours and 24 hours post-dosing, and at follow-up (5-7 days after final dose). ]
- Mean (SD) Change in FGF19 from Day 1 Pre-Dose to 24 h Post-Dose [ Time Frame: Pharmacodynamic blood samples were taken pre-dose and at 4 hours and 24 hours post-dosing, and at follow-up (5-7 days after final dose). ]
- Mean (SD) Change in C4 from Day 1 Pre-Dose to 4 h Post-Dose [ Time Frame: Pharmacodynamic blood samples were taken pre-dose and at 4 hours and 24 hours post-dosing, and at follow-up (5-7 days after final dose). ]
- Mean (SD) Change in C4 from Day 1 Pre-Dose to 24 h Post-Dose [ Time Frame: Pharmacodynamic blood samples were taken pre-dose and at 4 hours and 24 hours post-dosing, and at follow-up (5-7 days after final dose). ]
- Mean (SD) Changes in Total Bile Acids for A4250 4 h compared to pre-dose [ Time Frame: Samples were taken pre-dose and post-dose at 4 hours and 24 hours. ]
- Mean (SD) Changes in Total Bile Acids for A4250 24 h compared to pre-dose [ Time Frame: Samples were taken pre-dose, and post-dose at 4 hours and 24 hours. ]
- Geometric (geometric CV%) Mean for AUC(0-12) on Day 7 for plasma FGF19 [ Time Frame: AUC(0-12) on Day 7 (only for Part II) ]
- Geometric (geometric CV%) Mean for AUC(0-12) on Day 7 for plasma C4 [ Time Frame: AUC(0-12) on Day 7 (only Part II) ]
- Geometric (geometric CV%) Mean for AUC(0-12) on Day 7 for plasma Total Bile Acids [ Time Frame: AUC(0-12) on Day 7 (only Part II) ]
- Mean (SD) Changes in Faecel Total Bile Acids from Day 1 Pre-Dose on Day 7 at 24 h Post-dose [ Time Frame: Change from Day 1 Pre-dose to Day 7 at 24 hours Post-dose ]
- Mean (SD) Change in Faecal Total Bile Acids Excreted (ng) from Day 1 Pre-Dose on Day 7 Post-Dose [ Time Frame: Change from Day 1 Pre-dose to Day 7 at 24 hours Post-dose ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Healthy males or non-pregnant, non-lactating healthy females
- BMI of 18 to 32 kg/m2 or, if outside the range, considered not clinically significant by the investigator
- Willing and able to communicate and participate in the whole study
- Provided written informed consent
- Agreed to use an adequate method of contraception
Exclusion Criteria:
- Had participated in a clinical research study within the previous 3 months
- Were study site employees, or immediate family members of a study site or sponsor employee
- Had previously been enrolled in this study
- History of any drug or alcohol abuse in the past 2 years
- Regular alcohol consumption, in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
- Current smokers and those who had smoked within the last 12 months. A breath carbon monoxide (CO) reading of greater than 10 ppm at screening
- Females of childbearing potential who were pregnant or lactating (female subjects must have had a negative urine pregnancy test at admission)
- Did not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
- Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator
- Positive drugs of abuse test result
- Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
- History of cardiovascular, renal, hepatic, chronic respiratory or GI disease as judged by the investigator
- Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients eg lactose or contraindications to cholestyramine/Questran
- Presence or history of clinically significant allergy requiring treatment as per the judgement of the investigator Hayfever was allowed unless it was active
- Donation or loss of greater than 400 mL of blood within the previous 3 months
- Were taking, or had taken, any prescribed or over-the-counter drug (other than up to 4 g per day paracetamol, hormone replacement therapy [HRT] and hormonal contraception) or herbal remedies in the 14 days before IMP administration unless they were not considered to have interfered with the objectives of the study, as agreed by the PI and sponsor's medical monitor on a case by case basis
- Failed to satisfy the investigator of fitness to participate for any other reason

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02963077
Study Director: | Mats Ekelund, MD | Albireo |
Responsible Party: | Albireo |
ClinicalTrials.gov Identifier: | NCT02963077 |
Other Study ID Numbers: |
A4250-001 2013-001175-21 ( EudraCT Number ) |
First Posted: | November 15, 2016 Key Record Dates |
Last Update Posted: | November 16, 2016 |
Last Verified: | November 2016 |
Liver Diseases Cholestasis Liver Cirrhosis, Biliary Cholestasis, Intrahepatic Alagille Syndrome Fibrosis Pathologic Processes Digestive System Diseases Bile Duct Diseases Biliary Tract Diseases Liver Cirrhosis Heart Defects, Congenital |
Cardiovascular Abnormalities Cardiovascular Diseases Abnormalities, Multiple Congenital Abnormalities Genetic Diseases, Inborn Cholestyramine Resin Anticholesteremic Agents Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents |